Utidelone can penetrate BBB due to its unique physicochemical characteristics and insusceptibility to P-glycoprotein-mediated efflux
Ibara will drive AI-powered clinical research innovation
Partners with Yifan Pharmaceutical to launch Synovian injection for osteoarthritis in China
An investigational CYP11A1 Inhibitor, for the treatment of metastatic castration-resistant prostate cancer
Zealand Pharma anticipates initiation of a Phase 2b clinical trial in H2 2024
Detailed data from Phase 3 ECHELON-3 study demonstrate investigational ADCETRIS regimen reduced risk of death by 37 percent compared to chemotherapy alone
India's healthcare sector anticipates telemedicine reaching US$ 5.4 billion by 2025, with AI growing at 45% by 2024 and Healthtech jobs increasing 15-20%
Approval based on DUO-E trial results, which showed Imfinzi reduced the risk of disease progression or death by 58% vs. chemotherapy
First and only BTK inhibitor to demonstrate favourable overall survival trend vs. standard-of-care chemoimmunotherapy in this setting
Augtyro is the only FDA-approved treatment option for NTRK-positive tumors studied in both TKI-naïve and TKI-pretreated patients across solid tumors
Subscribe To Our Newsletter & Stay Updated
